

Committee Advice Documents - Safety Assessments

Genetically modified GHB811 cotton - RP1232

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Genetically modified GHB811 cotton](#)

Genetically modified GMB151 soybean - RP1123

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Genetically modified GMB151 soybean](#)

Genetically modified DP4114xMON810xMIR604xNK603 Maize and sub-combinations - RP1506

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Genetically modified DP4114xMON810xMIR604xNK603 Maize and sub-combinations](#)

Genetically modified 73496 oilseed rape - RP1372

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Genetically modified 73496 oil seedrape](#)

Calcidiol (25-hydroxycholecalciferol monohydrate) - RP35

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Calcidiol \(25-hydroxycholecalciferol monohydrate\) RP35](#)

Synthetic cannabidiol (CBD) - RP07

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Synthetic cannabidiol \(CBD\) RP07](#)

Cannabidiol (CBD) isolate - RP350

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Cannabidiol \(CBD\) isolate - RP350](#)

Schizochytrium sp.oil rich in DHA and EPA - RP1411

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Schizochytrium sp. oil rich in DHA and EPA - RP1411](#)

Magnesium L-threonate - RP956

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Magnesium L-threonate as a novel food for use in food supplements - RP956](#)

Barley Rice Protein - RP19

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Barley Rice Protein - RP19](#)

Cetylated Fatty Acids - RP200

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Cetylated Fatty Acids - RP200](#)

3-fucosyllactose (3-FL) - RP1202

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[3-fucosyllactose \(3-FL\) - RP1202](#)

Lacto-N-fucopentaose I (LNFP-I) and 2'-fucosyllactose (2'-FL) - RP549

This Committee Advice Document outlines the conclusions reached on the areas of the regulated product assessment where the Committee were asked to review. These are used to inform the FSA/FSS Safety Assessment for the application.

[Lacto-N-fucopentaose I \(LNFP-I\) and 2'-fucosyllactose \(2'-FL\) - RP549](#)